A PD-1-Targeted, Receptor-Masked IL-2 Immunocytokine That Engages IL-2Rα Strengthens T Cell-Mediated Anti-Tumor Therapies

The authors showed that interleukin-2 receptor alpha (IL-2Rα) engagement was critical for the anti-tumor activity of systemic IL-2 therapy.